Clinical Trial Update: A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome [Phase 3]

View source ↗

Summary

Phase 3 study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese adults with Familial Chylomicronemia Syndrome has completed, and results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome

Drugs mentioned

• ARO-APOC3 (APOC3 antisense oligonucleotide)
• SAR449124 (Plozasiran)
• VSA001

Snippet

Sponsor: Visirna Therapeutics HK Limited | Conditions: Familial Chylomicronemia Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2026-02-27